基于游离DNA的无创产前筛查检测22q11.2缺失综合征
本研究在6个国家21个中心前瞻性纳入20,887名孕妇,评估基于单核苷酸多态性的游离DNA产前筛查对22q11.2缺失综合征的检测性能。共确认12例22q11.2缺失综合征,筛查灵敏度为75.0%,特异度为99.84%,阳性预测值为23.7%,阴性预测值为99.98%。更新算法检出12例中的10例(83.3%),假阳性率更低(0.05% vs 0.16%,P<.001),阳性预测值为52.6%。
要点
- 基于单核苷酸多态性的游离DNA产前筛查可检出大多数22q11.2缺失综合征病例,包括较小的嵌套缺失。
- 总队列中筛查灵敏度为75.0%,特异度为99.84%,阳性预测值为23.7%,阴性预测值为99.98%。
- 更新算法检出12例中的10例(83.3%),假阳性率0.05% vs 0.16%(P<.001),阳性预测值为52.6%。
核心结论
- 基于游离DNA的无创产前筛查可检测大多数22q11.2缺失综合征病例,包括较小的嵌套缺失,且假阳性率低。
研究设计与样本
- 前瞻性研究,在6个国家21个中心纳入接受基于单核苷酸多态性的游离DNA产前筛查的孕妇,共20,887名入组,18,289名(87.6%)获得遗传学结局。
- 对所有病例请求产前或新生儿DNA样本,通过染色体微阵列进行遗传学确认。
主要发现
- 队列中确认12例22q11.2缺失综合征,包括5例(41.7%)嵌套缺失,患病率为1/1524。
- 总队列中,17,976例(98.3%)被判定为低风险,38例(0.2%)为高风险,275例(1.5%)为不可报告。
- 12例22q11.2缺失综合征中检出9例,灵敏度75.0%(95%CI 42.8-94.5),特异度99.84%(95%CI 99.77-99.89),阳性预测值23.7%(95%CI 11.44-40.24),阴性预测值99.98%(95%CI 99.95-100)。
- 不可报告结果的病例中无一例诊断为22q11.2缺失综合征。
- 更新算法检出12例中的10例(83.3%,95%CI 51.6-97.9),假阳性率0.05% vs 0.16%(P<.001),阳性预测值52.6%(10/19,95%CI 28.9-75.6)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Historically, prenatal screening has focused primarily on the detection of fetal aneuploidies. Cell-free DNA now enables noninvasive screening for subchromosomal copy number variants, including 22q11.2 deletion syndrome (or DiGeorge syndrome), which is the most common microdeletion and a leading cause of congenital heart defects and neurodevelopmental delay. Although smaller studies have demonstrated the feasibility of screening for 22q11.2 deletion syndrome, large cohort studies with confirmatory postnatal testing to assess test performance have not been reported. OBJECTIVE: This study aimed to assess the performance of single-nucleotide polymorphism-based, prenatal cell-free DNA screening for detection of 22q11.2 deletion syndrome. STUDY DESIGN: Patients who underwent single-nucleotide polymorphism-based prenatal cell-free DNA screening for 22q11.2 deletion syndrome were prospectively enrolled at 21 centers in 6 countries. Prenatal or newborn DNA samples were requested in all cases for genetic confirmation using chromosomal microarrays. The primary outcome was sensitivity, specificity, positive predictive value, and negative predictive value of cell-free DNA screening for the detection of all deletions, including the classical deletion and nested deletions that are ≥500 kb, in the 22q11.2 low-copy repeat A-D region. Secondary outcomes included the prevalence of 22q11.2 deletion syndrome and performance of an updated cell-free DNA algorithm that was evaluated with blinding to the pregnancy outcome. RESULTS: Of the 20,887 women enrolled, a genetic outcome was available for 18,289 (87.6%). A total of 12 22q11.2 deletion syndrome cases were confirmed in the cohort, including 5 (41.7%) nested deletions, yielding a prevalence of 1 in 1524. In the total cohort, cell-free DNA screening identified 17,976 (98.3%) cases as low risk for 22q11.2 deletion syndrome and 38 (0.2%) cases as high risk; 275 (1.5%) cases were nonreportable. Overall, 9 of 12 cases of 22q11.2 were detected, yielding a sensitivity of 75.0% (95% confidence interval, 42.8-94.5); specificity of 99.84% (95% confidence interval, 99.77-99.89); positive predictive value of 23.7% (95% confidence interval, 11.44-40.24), and negative predictive value of 99.98% (95% confidence interval, 99.95-100). None of the cases with a nonreportable result was diagnosed with 22q11.2 deletion syndrome. The updated algorithm detected 10 of 12 cases (83.3%; 95% confidence interval, 51.6-97.9) with a lower false positive rate (0.05% vs 0.16%; P<.001) and a positive predictive value of 52.6% (10/19; 95% confidence interval, 28.9-75.6). CONCLUSION: Noninvasive cell-free DNA prenatal screening for 22q11.2 deletion syndrome can detect most affected cases, including smaller nested deletions, with a low false positive rate.
引用
- Dar P, Jacobsson B, Clifton R, et al. Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome. Am J Obstet Gynecol. 2022. PMID: 35033576. doi:10.1016/j.ajog.2022.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。